Spyre Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Spyre Therapeutics, Inc. quarterly Share-based Payment Arrangement, Expense history and growth rate from Q1 2015 to Q2 2024.
  • Spyre Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $8.68M, a 354% increase year-over-year.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $8.68M +$6.77M +354% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $13.8M +$12.1M +710% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q3 2023 $4.79M +$3.22M +206% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $1.91M -$107K -5.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $1.71M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q3 2022 $1.57M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $2.02M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2016 $140K +$102K +268% Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-19
Q1 2015 $38K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.